ROTH
PharmaRoth Labs, Inc. [ROTH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ROTH Stock Summary
In the News
ROTH Financial details
Company Rating
Buy
Market Cap
301
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-0.01
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
171%
ROC
-37.45%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-6-1.0E-4
52W High
-
52W Low
-
RSI
-
Rel Volume
0.48
Avg Volume
41.4K
Volume
20K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-99%
-
-
-
-
Beta
-3.517
-
-
Volatility
0%, 0%
Prev Close
0%
Price
1.0E-6
Change
0%
ROTH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 0 | 0 | 0 | 0 | 0 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 0 | 0 | 0 | 0 | 0 | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 0 | 0 | 0 | 0 | 0 | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2011-03-31 for Q1
| Metric | History | 2010-03-31 | 2010-06-30 | 2010-09-30 | 2010-12-31 | 2011-03-31 |
|---|---|---|---|---|---|---|
| 2.01K | 2.01K | 2.01K | 2.01K | 2.01K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | |
| P/E ratio | 0 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
| PTB ratio | 0 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
| Current ratio | 0 | 0 | 0 | 0 | 0 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 0 | 0 | 0 | 0 | |
| ROIC | 0 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | 0 | 0 | 0 | 0 | 0 | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 0 | 0 | 0 | 0 | 0 | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ROTH Frequently Asked Questions
What is PharmaRoth Labs, Inc. stock symbol ?
PharmaRoth Labs, Inc. is a US stock , located in Las vegas of Nv and trading under the symbol ROTH
What is PharmaRoth Labs, Inc. stock quote today ?
PharmaRoth Labs, Inc. stock price is $1.0E-6 today.
Is PharmaRoth Labs, Inc. stock public?
Yes, PharmaRoth Labs, Inc. is a publicly traded company.
Company Profile
- Volume Average 41.4K
- Market Capitalization 301
- CEO Mr. Luis Manuel Ornelas Lopez
- Headquarters Las Vegas,NV,US
- IPO Date 2008-12-11
-
Website
http://www.feroindustries.com 
PharmaRoth Labs, Inc. operates as a nutraceutical company worldwide. It focuses on producing, marketing, and distributing Sucanon, an herbal-based nutraceutical treatment for type-2 diabetes. The company was formerly known as Fero Industries Inc. and changed its name to PharmaRoth Labs, Inc. in March 2013. PharmaRoth Labs, Inc. was founded in 2000 and is based in Las Vegas, Nevada.
